Travere Therapeutics, Inc. (0001438533) (Filer) — SEC 8-K Filing
Travere Therapeutics
May 11, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
Hims & Hers has agreed to acquire telehealth startup Eucalyptus in a deal worth up to USD1.15 billion. The transaction is positioned as a major liquidity event for Eucalyptus’ early backers and employees who took equity rather than salary.
The article describes Eucalyptus as rewarding staff with shares from early in its life, creating a broad base of Australian angel investors and venture capital participation over multiple early rounds. It also notes that Eucalyptus engaged Barrenjoey’s Justin Dwyer and Goldman Sachs in New York for advice, with additional advisers including G+T and PwC, and legal support from MinterEllison for Hims & Hers.
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Travere Therapeutics
May 11, 2026
Pharvaris
May 11, 2026
Partner Therapeutics→Bizengri (bispecific antibody)
May 11, 2026
The Surgery Center of Southern Oregon
May 11, 2026
Mobia Medical
May 11, 2026